The difficulty is that it's not licensed for use at the moment. Now, medicines licensing is not devolved. Once a medicine is licensed, the use of it then is governed by NICE and the All Wales Medicines Strategy Group, but, of course, for GPs, GPs are governed—I know Dai Lloyd is over there—as I understand it, by rules that tell them what they cannot prescribe, not what they can prescribe. So, it is possible for a GP to prescribe melatonin; it's a matter for individual prescribers. There's no restriction on GPs doing that, but, of course, any GP is going to ask the question, 'Well, is this something I should be doing? Is it something that I regard as clinically safe?' That's inevitable, and they do take clinical responsibility for the medicines that they prescribe. The British Medical Association does say to GPs that they should not prescribe beyond their own knowledge or capability—sensible advice—and I can imagine GPs being nervous about prescribing what appears to be a medicine unlicensed for use in children.

The next step has to be to look at evidence to make sure that it is licensed for use in children, and then of course to move on from there. What I can say, however, is, in the meantime, we have established a new service to assess, diagnose and provide ongoing support for children and young people with neurodevelopmental conditions, and we are investing £2 million a year to do so.